Λέξεις-κλειδιά:
azathioprine; B lymphocyte antibody; belimumab; calcineurin inhibitor; cyclophosphamide; glucocorticoid; mycophenolate mofetil; placebo; rituximab; belimumab; immunosuppressive agent; monoclonal antibody, add on therapy; drug efficacy; Editorial; estimated glomerular filtration rate; human; infection; lupus erythematosus nephritis; phase 3 clinical trial (topic); priority journal; prognosis; randomized controlled trial (topic); risk benefit analysis; treatment response; lupus erythematosus nephritis, Antibodies, Monoclonal, Humanized; Humans; Immunosuppressive Agents; Lupus Nephritis
